Sanofi-Genzyme files preemptive legal strike to protect eczema drug – Boston Business Journal

These Mass. biotechs could get drugs approved in 2017

David Meeker is the head of Sanofi-Genzyme, which expects to soon win approval for more

W. Marc Bernsau | Boston Business Journal

Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen.

The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (NYSE: SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (Nasdaq: REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (Nasdaq: AMGN).

David Meeker is the head of Sanofi-Genzyme, which expects to soon win approval for more

W. Marc Bernsau | Boston Business Journal

The treatment for atopic dermatitis, which will be sold under the brand name Dupixent, is expected to win FDA approval by March 29. In the complaint, Sanofi-Genzyme and Regeneron described the drug as a game-changer, citing its success in clinical trials.

See more here:
Sanofi-Genzyme files preemptive legal strike to protect eczema drug - Boston Business Journal